Tyra Biosciences (TYRA) Liabilities and Shareholders Equity (2020 - 2026)

Tyra Biosciences has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $412.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 19.96% year-over-year to $412.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (down 10.95% YoY), and the FY2025 full-year result was $282.6 million, down 22.27% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $412.0 million, up from $282.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $412.0 million in Q1 2026, with the low at $225.9 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $311.8 million across 5 years, with a median of $299.0 million in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 60.97% — and 2025, when it fell 22.27%.
• Tyra Biosciences' Liabilities and Shareholders Equity stood at $266.2 million in 2022, then slipped by 15.15% to $225.9 million in 2023, then surged by 60.97% to $363.6 million in 2024, then slipped by 22.27% to $282.6 million in 2025, then surged by 45.8% to $412.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $412.0 million (Q1 2026), $282.6 million (Q4 2025), and $301.9 million (Q3 2025), per Business Quant data.